Andrew Scott's Appointment at Turn Therapeutics
Turn Therapeutics Inc. (NASDAQ: TTRX), a pioneer in the biotechnology realm focused on dermatologic, advanced wound, and infectious disease therapies, has announced the new appointment of Andrew Scott as Vice President of Corporate Communications. This role is particularly significant as the company transitions into an exciting growth phase.
Strategic Role of Corporate Communications
In his new position, Andrew will lead the company's efforts in investor relations, capital markets strategy, and corporate communications. His expertise is expected to provide substantial support to Turn's licensing and partnership initiatives, critical for the company's development trajectory.
The Vision Ahead
Bradley Burnam, Founder and Chief Executive Officer of Turn Therapeutics, expressed his enthusiasm for Andrew joining the team. "His extensive experience arrives at a pivotal time for us, as we have recently gone public and strengthened our financial position. We are eager to tap into his knowledge to enhance our investor engagement and ensure our story reaches key stakeholders, particularly as we approach vital milestones this year, including the completion of our Phase 2 clinical program," said Burnam.
Andrew Scott's Background
Scott comes to Turn Therapeutics with over three decades of experience in capital markets and corporate finance. He previously held a prominent role at ThinkEquity LLC as Managing Director of Investment Banking and has been instrumental in raising nearly $3 billion through diverse transactions in the life sciences. His strong background in business development further positions him to effectively advance Turn's initiatives.
Education and Early Career
Scott's academic credentials include a Bachelor of Business Administration in Accounting from Pace University, which forms a solid foundation for his professional journey in the financial domain.
About Turn Therapeutics
Turn Therapeutics is dedicated to the development and commercialization of products specifically targeting dermatological conditions, wound care, and infectious diseases. The company boasts three FDA clearances for its unique formulations aimed at treating wounds and skin conditions. Currently, Turn is focusing on late-stage clinical trials for conditions like eczema and onychomycosis.
Commitment to Global Health
In addition to its therapeutic developments, Turn Therapeutics is actively pursuing initiatives that enhance global health, such as the creation of thermostable vaccine delivery systems aimed at underserved populations around the world. This commitment underscores Turn's mission to innovate public health solutions.
Investor Relations
For those interested in learning more about the company’s financial updates or investment opportunities, the contact for investor relations is Monique Kosse, Managing Director of the Gilmartin Group. She can be reached via email at Investors@TurnTherapeutics.com.
Media Contact
For media inquiries, please contact Turn Therapeutics directly at media@TurnTherapeutics.com.
Frequently Asked Questions
What is Turn Therapeutics?
Turn Therapeutics is a biotechnology company engaged in developing treatments for dermatological issues, wound care, and infectious diseases.
What recent announcement did Turn Therapeutics make?
Turn Therapeutics announced the appointment of Andrew Scott as Vice President of Corporate Communications, a strategic role aimed at guiding their growth.
What is Andrew Scott's experience?
Andrew Scott has over 30 years of experience in capital markets and corporate finance, having previously held significant positions including Managing Director at ThinkEquity LLC.
What is Turn Therapeutics focused on currently?
The company is focused on late-stage clinical trials for eczema and onychomycosis while also working on global health initiatives.
How can I contact Turn Therapeutics for more information?
For investor relations, email Monique Kosse at Investors@TurnTherapeutics.com. For media inquiries, you can reach them at media@TurnTherapeutics.com.
